Crossmark

ETS‐targeted therapy: can it substitute for MEK inhibitors?

Crossref DOI link: https://doi.org/10.1186/s40169-017-0147-4

Published Online: 2017-05-02

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tetsu, Osamu http://orcid.org/0000-0003-1820-7539
McCormick, Frank
Funding

Funding for this research was provided by:

National Cancer Institute (1R35CA197709)

The Joan and Irwin Jacobs Fund of the Jewish Community Foundation (N/A)

National Cancer Institute (1R35CA197709)
License Information

Version of Record valid from 2017-05-02

Text and Data Mining valid from 2017-05-02

Version of Record valid from 2017-05-02
More Information

Article History

Received: 24 January 2017

Accepted: 11 April 2017

First Online: 2 May 2017